Business Description

IDEXX Laboratories Inc
NAICS : 325412
SIC : 2835
ISIN : US45168D1046
Share Class Description:
MEX:IDXX: Ordinary SharesDescription
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.16 | |||||
Equity-to-Asset | 0.45 | |||||
Debt-to-Equity | 0.73 | |||||
Debt-to-EBITDA | 0.82 | |||||
Interest Coverage | 37.01 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 19.74 | |||||
Beneish M-Score | -2.56 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 8 | |||||
3-Year EBITDA Growth Rate | 8.4 | |||||
3-Year EPS without NRI Growth Rate | 9.8 | |||||
3-Year FCF Growth Rate | 9.3 | |||||
3-Year Book Growth Rate | 33.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 12.83 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 7.43 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 59.73 | |||||
9-Day RSI | 56.27 | |||||
14-Day RSI | 61.14 | |||||
3-1 Month Momentum % | 18.57 | |||||
6-1 Month Momentum % | 22.06 | |||||
12-1 Month Momentum % | 16.15 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.16 | |||||
Quick Ratio | 0.81 | |||||
Cash Ratio | 0.14 | |||||
Days Inventory | 92.93 | |||||
Days Sales Outstanding | 47.4 | |||||
Days Payable | 27.8 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 1.2 | |||||
Shareholder Yield % | 2.66 |
Profitability Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 61.28 | |||||
Operating Margin % | 29.14 | |||||
Net Margin % | 22.76 | |||||
EBITDA Margin % | 32.8 | |||||
FCF Margin % | 21.32 | |||||
ROE % | 57.29 | |||||
ROA % | 26.91 | |||||
ROIC % | 35.72 | |||||
3-Year ROIIC % | 20.1 | |||||
ROC (Joel Greenblatt) % | 92.98 | |||||
ROCE % | 50.95 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat score | 8 | |||||
Tariff score | 8 |
GF Value Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 50.15 | |||||
Forward PE Ratio | 43.9 | |||||
PE Ratio without NRI | 47.85 | |||||
Shiller PE Ratio | 75.14 | |||||
Price-to-Owner-Earnings | 56.13 | |||||
PEG Ratio | 3.07 | |||||
PS Ratio | 11.42 | |||||
PB Ratio | 30.26 | |||||
Price-to-Tangible-Book | 46.94 | |||||
Price-to-Free-Cash-Flow | 53.58 | |||||
Price-to-Operating-Cash-Flow | 46.35 | |||||
EV-to-EBIT | 38.55 | |||||
EV-to-Forward-EBIT | 36.06 | |||||
EV-to-EBITDA | 34.54 | |||||
EV-to-Forward-EBITDA | 32.04 | |||||
EV-to-Revenue | 11.33 | |||||
EV-to-Forward-Revenue | 10.81 | |||||
EV-to-FCF | 53.16 | |||||
Price-to-GF-Value | 0.95 | |||||
Price-to-Projected-FCF | 4.53 | |||||
Price-to-DCF (Earnings Based) | 1.45 | |||||
Price-to-DCF (FCF Based) | 1.7 | |||||
Price-to-Median-PS-Value | 1.16 | |||||
Price-to-Peter-Lynch-Fair-Value | 3.3 | |||||
Price-to-Graham-Number | 9.99 | |||||
Earnings Yield (Greenblatt) % | 2.59 | |||||
FCF Yield % | 1.92 | |||||
Forward Rate of Return (Yacktman) % | 15.89 |